Clinical trials: Advanced RCC
Kidney Cancer
S0351, CNTO 328 in Treating Patients With Unresectable or Metastatic Kidney Cancer
RATIONALE: Monoclonal antibodies, such as CNTO 328, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00311545
- Testing
- CNTO 328
- Sponsor
- SWOG Cancer Research Network
Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck
A Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies
This is a Phase 1, open-label, dose-escalation and dose-expansion study to evaluate the safety, tolerability, pharmacokinetic (PK), pharmacodynamic (PD) and clinical activity of etrumadenant (AB928) in combination with…
- Conditions
- Non-small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Breast Cancer, Colorectal Cancer
- Trial name
- NCT03629756
- Testing
- Etrumadenant, Zimberelimab
- Where
- 15 sites in United States, Australia
- Volunteers
- 48 people
- Sponsor
- Arcus Biosciences, Inc.
Advanced Clear Cell Renal Carcinoma
Vandetanib to Treat Advanced Kidney Cancer
Background: One way tumors are able to grow is by forming new blood vessels that supply it with nutrients and oxygen. Vandetanib (ZD6474) is an experimental drug that blocks certain proteins on the surface of tumor and blood…
- Trial name
- NCT01372813
- Testing
- vandetanib
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor, Advanced Cancer
A Study of MGC026 in Participants With Advanced Solid Tumors
The study is designed to understand the safety, tolerability, pharmacokinetics, immunogenicity, and preliminary antitumor activity of vobramitamab tavatecan (MGC026) in participants with relapsed or refractory, unresectable…
- Conditions
- Advanced Solid Tumor, Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Trial name
- NCT06242470
- Testing
- MGC026 Dose Escalation, MGC026 Dose for Expansion, Pembrollizumab
- Where
- 12 sites in United States, Australia and 1 more
- Volunteers
- 394 people
- Sponsor
- MacroGenics
Locally Advanced or Metastatic Renal Cell Carcinoma
Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint Inhibitors
The overall objective of this study is to evaluate the efficacy and safety of cabozantinib as 2nd line treatment in subjects with unresectable, locally advanced or metastatic RCC with a clear-cell component, who progressed after…
- Trial name
- CaboPoint (NCT03945773)
- Testing
- Cabozantinib
- Where
- 40 sites in Austria, France and 5 more
- Volunteers
- 127 people
- Sponsor
- Ipsen
Advanced Solid Tumor, Metastatic Solid Tumor
A Study of GI-108, an Anti-CD73-IgG4 Fc-IL-2v Bispecific Fusion Protein, as Monotherapy in Patients With Advanced or Metastatic Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and therapeutic activity of GI-108, as a single agent, in patients with advanced or metastatic solid tumors
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Non-small Cell Lung Cancer (NSCLC), Head and Neck (HNSCC)
- Trial name
- NCT07172802
- Testing
- GI-108
- Where
- 3 sites in South Korea
- Volunteers
- 102 people
- Sponsor
- GI Innovation, Inc.
Metastatic Tumor, Advanced Solid Tumor
A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors
This is a phase I clinical study to evaluate the safety and tolerability of CAR-T in patients with CD70-positive advanced/metastatic solid tumors, and to obtain the maximum tolerated dose of CAR-T and phase II Recommended dose.
- Conditions
- Metastatic Tumor, Advanced Solid Tumor, Renal Cell Carcinoma, Ovarian Cancer
- Trial name
- NCT05420545
- Testing
- CD70 CAR-T cells
- Where
- China
- Volunteers
- 36 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
Metastatic Renal Cell Carcinoma
Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC
SUNNIFORECAST (Standard of Care vs. Nivolumab + Ipilimumab as First line treatment of renal cell cancer of non-clear cell subtypes) is a Phase II, randomized, open-label investigator initiated trial (IIT) of Nivolumab…
- Trial name
- NCT03075423
- Testing
- Ipilimumab plus nivolumab, Standard Therapy
- Where
- 30 sites in Belgium, Czechia and 5 more
- Volunteers
- 316 people
- Sponsor
- Goethe University
HER2 Positive Gastric Cancer, Colorectal Cancer
FATE-NK100 as Monotherapy and in Combination With Monoclonal Antibody in Subjects With Advanced Solid Tumors
This is a Phase 1, single-dose, open-label, dose-escalation study. The study will be conducted in three parts (i.e. regimens) in an outpatient setting as follows: Regimen A: FATE-NK100 as a monotherapy in subjects with advanced…
- Conditions
- HER2 Positive Gastric Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma, EGFR Positive Solid Tumor
- Trial name
- NCT03319459
- Testing
- FATE-NK100, Cetuximab, Trastuzumab
- Where
- 4 sites in United States
- Volunteers
- 44 people
- Sponsor
- Fate Therapeutics
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Renal Cell Carcinoma
Everolimus and Bevacizumab in Advanced Non-Clear Cell Renal Cell Carcinoma (RCC)
The purpose of this study is to find out what effects, good and/or bad the combination of two medications, everolimus and bevacizumab, has on kidney cancer.
- Trial name
- NCT01399918
- Testing
- everolimus and bevacizumab
- Where
- 7 sites in United States
- Volunteers
- 57 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Renal Cell Carcinoma
Clinical Study With Axitinib In Advanced Kidney Cancer, Who Have Failed First Line Treatment
This is a single arm study with axitinib in patients with advanced kidney cancer (clear cell variant), who have failed first line therapy.
- Trial name
- NCT01473043
- Testing
- Axitinib
- Where
- 4 sites in Australia, Canada
- Sponsor
- Pfizer
Advanced Renal Cell Carcinoma (All Subtypes), Metastatic Renal Cell Carcinoma (All Subtypes)
CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional Study
This is a non-interventional study to retrospectively evaluate the safety and to describe the effectiveness of cabozantinib after immunoncologic treatment with nivolumab or nivolumab plus ipilimumab in routine clinical practice.
- Trial name
- NCT04147143
- Testing
- Documentation
- Where
- 2 sites in Germany
- Volunteers
- 56 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma
Study CB-839 in Combination With Nivolumab in Patients With Melanoma, Clear Cell Renal Cell Carcinoma (ccRCC) and Non-Small Cell Lung Cancer (NSCLC)
This study is an open-label Phase 1/2 evaluation of CB-839 in combination with nivolumab in participants with clear cell renal cell carcinoma, melanoma, and non-small cell lung cancer.
- Conditions
- Clear Cell Renal Cell Carcinoma (ccRCC), Melanoma, Non-small Cell Lung Cancer (NSCLC)
- Trial name
- NCT02771626
- Testing
- CB-839, Nivolumab
- Where
- 17 sites in United States
- Volunteers
- 118 people
- Sponsor
- Calithera Biosciences, Inc
Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma
Sitravatinib and Nivolumab in Treating Patients With Advanced or Metastatic Kidney Cancer
This phase I/II trial studies the side effects of sitravatinib and how well it works with nivolumab in treating patients with kidney cancer that has spread to other places in the body.
- Conditions
- Clear Cell Renal Cell Carcinoma, Metastatic Kidney Carcinoma, Stage III Renal Cell Cancer AJCC v7, Stage IV Renal Cell Cancer AJCC v7
- Trial name
- NCT03015740
- Testing
- Laboratory Biomarker Analysis, Nivolumab, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma, Non-small Cell Lung Cancer
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors
- Conditions
- Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin), Renal Cell Carcinoma
- Trial name
- NCT07115043
- Testing
- AZD6750, rilvegostomig
- Where
- 13 sites in United States, Australia and 2 more
- Volunteers
- 120 people
- Sponsor
- AstraZeneca
Renal Cell Carcinoma
Study of Cabozantinib in Combination With Nivolumab and Ipilimumab in Patients With Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
This is a multicenter, randomized, double-blinded, controlled Phase 3 trial of cabozantinib in combination with nivolumab and ipilimumab versus nivolumab and ipilimumab in combination with matched placebo.
- Trial name
- COSMIC-313 (NCT03937219)
- Testing
- Cabozantinib, Nivolumab, Ipilimumab
- Where
- 159 sites in United States, Argentina and 23 more
- Volunteers
- 855 people
- Sponsor
- Exelixis
Locally Advanced or Metastatic Renal Cell Carcinoma
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
To understand the epidemiology, treatment patterns and outcomes of patients with metastatic Renal Cell Carcinoma (mRCC). Data from mRCC patients who received cabozantinib versus non-cabozantinib Tyrosine Kinase Inhibitor (TKI) (a…
- Trial name
- US NIS Cabo (NCT04353765)
- Testing
- Cabozantinib monotherapy, All authorized TKI monotherapies in advanced RCC per FDA label in advanced RCC
- Where
- United States
- Volunteers
- 247 people
- Sponsor
- Ipsen
Renal Cell Carcinoma
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as…
- Trial name
- NCT00876382
- Where
- 8 sites in United States
- Volunteers
- 47 people
- Sponsor
- SCRI Development Innovations, LLC
Kidney Cancer Stage Iv, Advanced Melanoma
Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma
This is a phase Ib, open, mono-center, dose-escalation, tolerability and pharmacokinetic study evaluating the Recombinant Humanized Anti-PD-1 mAb for Injection in combination with Axitinib in patients with advanced kidney cancer…
- Trial name
- NCT03086174
- Testing
- humanized anti-PD-1 monoclonal antibody Toripalimab
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.